← Leaderboards
Jer-Tsong Hsieh
University Of Texas Sw Med Ctr/Dallas
$5,200,733
Attributed
$7,683,052
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $813.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,683,052 · 9
By mechanism
R01$6,623,469 · 5
R41$455,000 · 1
R21$430,496 · 1
P50$174,087 · 1
P20$0 · 1
Top collaborators
- Zhi-Ping Liu7 shared
- Jian Yang5 shared
- Jung-Mo Ahn2 shared
- Xiankai Sun1 shared
- Bing Xu1 shared
Most similar at University Of Texas Sw Med Ctr/Dallas
Same institution · by research overlap
- Eric John Hansen$10,985,503
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignMalignant Neoplasm Of ProstateBaseMalignant NeoplasmsMetastatic Prostate CancerCancer TherapyCancer CellIn VivoTreatment EfficacyCastration Resistant Prostate CancerResistanceCellsProstate Cancer CellHormonesTumorSuccessDrug ResistanceAnimal ModelEffective TherapyLeadPhenotypeCancer PatientMolecular ImagingChemotherapy
Grant awards (29)
Overcoming mechanisms of PTPN1 driving therapy- and castration- resistant prostate cancer with novel theranostics$472,458
R01 · FY2025 · CA · contact PI
Targeting KDM4B, a novel alternative splicing regulator, in castration-resistant prostate cancer (CRPC)$405,500
R01 · FY2022 · CA
Development of small molecule epigenetic therapeutics for prostate cancer$55,000
R41 · FY2022 · CA
Targeting KDM4B, a novel alternative splicing regulator, in castration-resistant prostate cancer (CRPC)$413,776
R01 · FY2021 · CA
Development of small molecule epigenetic therapeutics for prostate cancer$400,000
R41 · FY2021 · CA
Exploring enzyme-instructed self-assembly (EISA) for targeting osteoblastic metastasis of prostate cancer$430,496
R21 · FY2020 · CA
Targeting KDM4B, a novel alternative splicing regulator, in castration-resistant prostate cancer (CRPC)$231,063
R01 · FY2020 · CA
Targeting KDM4B, a novel alternative splicing regulator, in castration-resistant prostate cancer (CRPC)$401,363
R01 · FY2019 · CA
Targeting KDM4B, a novel alternative splicing regulator, in castration-resistant prostate cancer (CRPC)$429,276
R01 · FY2018 · CA
Developing targeted therapy with prostate cancer specific nanomedicine$314,920
R01 · FY2017 · CA · contact PI
Developing targeted therapy with prostate cancer specific nanomedicine$315,210
R01 · FY2016 · CA · contact PI
Targeting aggressive prostate cancer with novel theranostic nanomedicine$326,384
R01 · FY2015 · CA · contact PI
Developing targeted therapy with prostate cancer specific nanomedicine$312,584
R01 · FY2015 · CA · contact PI
Targeting aggressive prostate cancer with novel theranostic nanomedicine$314,875
R01 · FY2014 · CA · contact PI
Developing targeted therapy with prostate cancer specific nanomedicine$303,466
R01 · FY2014 · CA · contact PI
Developing targeted therapy with prostate cancer specific nanomedicine$327,859
R01 · FY2013 · CA · contact PI
Targeting aggressive prostate cancer with novel theranostic nanomedicine$305,137
R01 · FY2013 · CA · contact PI
Targeting aggressive prostate cancer with novel theranostic nanomedicine$323,662
R01 · FY2012 · CA · contact PI
Targeting aggressive prostate cancer with novel theranostic nanomedicine$337,563
R01 · FY2011 · CA · contact PI
The role of CAR and its application in bladder cancer$261,253
R01 · FY2006 · CA · contact PI
The role of CAR and its application in bladder cancer$267,540
R01 · FY2005 · CA
The role of CAR and its application in bladder cancer$267,540
R01 · FY2004 · CA
The role of CAR and its application in bladder cancer$292,040
R01 · FY2003 · CA
SIGNAL TRANSDUCTION DEFECTS IN PROSTATE DISEASE$0
P50 · FY2002 · DK
ADENOVIRUS BASED GENE THERAPY OF UROGENITAL CANCERS$0
P20 · FY2002 · CA
ADENOVIRUS BASED GENE THERAPY OF UROGENITAL CANCERS$0
P20 · FY2001 · CA
SIGNAL TRANSDUCTION DEFECTS IN PROSTATE DISEASE$0
P50 · FY2001 · DK
SIGNAL TRANSDUCTION DEFECTS IN PROSTATE DISEASE$0
P50 · FY2001 · DK
SIGNAL TRANSDUCTION DEFECTS IN PROSTATE DISEASE$174,087
P50 · FY2000 · DK